Status:
COMPLETED
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Conditions:
Active Rheumatoid Arthritis
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.
Eligibility Criteria
Inclusion
- Diagnosis of early rheumatoid arthritis.
- Methotrexate (MTX) naive.
- Active early rheumatoid arthritis at the time of enrollment.
Exclusion
- Previous or current treatment with etanercept, other tumor necrosis factor-alpha (TNF) inhibitors, or other biologic agents.
- Concurrent treatment with any disease-modifying anti-rheumatoid drugs (DMARD), within 4 weeks before baseline.
- Concurrent treatment with more than 1 non-steroidal anti-inflammatory drug (NSAID) at baseline.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
306 Patients enrolled
Trial Details
Trial ID
NCT00913458
Start Date
September 1 2009
End Date
December 1 2012
Last Update
July 17 2014
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Lyon, France, 69437
2
Pfizer Investigational Site
Montpellier, France, 34293
3
Pfizer Investigational Site
Paris, France, 75018
4
Pfizer Investigational Site
Paris, France, 75651